CER Translation and Clinical Evaluation Report Services
Risk-based CER translation by qualified medical and clinical linguists, with terminology control, evidence-aware review and traceable certificates under MDR.
What CERs are
Clinical Evaluation Reports (CERs) and supporting documents are used to demonstrate the clinical safety, performance and benefit-risk profile of a medical device under MDR. They typically include intended purpose, equivalence discussions, clinical evidence summaries, literature evaluations, PMS and PMCF inputs, benefit-risk conclusions and references that inform notified body interactions.
Who needs CER translation
CER translation is typically requested by Clinical Affairs Managers, CER Writers, Medical Writers and Regulatory Affairs Managers managing multilingual clinical evaluation documentation across MedTech portfolios. It supports manufacturers handling CER updates, market expansions, SSCP-related content and authority-facing materials across the languages each Member State or use case requires.
Why accurate translation matters
CER translation must accurately and completely reflect the approved source content, with controlled clinical terminology, evidence wording, benefit-risk conclusions, performance claims, references and version alignment. Translation errors can affect how clinical evidence reads across languages, how internal reviewers interpret findings and how notified body interactions are supported by the multilingual documentation.
Risk-based clinical workflows
AbroadLink applies risk-based workflows to manage the risk of failing to achieve accurate CER translation. Lower-risk supporting documents or administrative sections may use different workflows when device, content and client-side controls support that choice. Higher-risk evidence and benefit-risk content uses stronger workflows, without changing the accuracy expectation itself.
Benefits of Risk-Based CER Translation
CER translation services support clinical and regulatory teams managing MDR clinical documentation, evidence summaries, benefit-risk conclusions and recurring CER updates. A risk-based approach matches workflow depth to device, document section, clinical complexity and translation risk, supporting predictable quality across CER cycles and related regulated content.
Preserved clinical meaning
Qualified medical and clinical linguists translate CER content with attention to intended purpose, clinical evidence, benefit-risk wording and references that literal translation often distorts across languages and document sections.
Consistency with PMCF, PMS, SSCP
Translation memories and approved terminology keep CER content consistent with PMCF, PMS, SSCPs, IFUs and technical documentation.
MDR clinical documentation support
MDR clinical documentation translation under workflows aligned with Regulation (EU) 2017/745 expectations, with MDR-aligned terminology, evidence-aware review and traceability through CertLink.
Evidence and benefit-risk awareness
Clinical evidence summaries, equivalence discussions, benefit-risk conclusions, performance claims and safety statements are handled by linguists with medical device translation experience appropriate to CER content.
Risk-aligned workflows
Workflow depth matches device class, CER section, document complexity and translation risk, supporting efficient processing for appropriate content and stronger review where translation error could carry greater consequences.
Audit-ready traceability
Signed translation certificates accessible through CertLink identify documents, project codes, translators and AI models used, supporting Clinical Affairs, QARA, PRRC and notified body interactions.
Common Challenges in Clinical Evaluation Translation
When CERs or supporting clinical evaluation documents are translated without clinical expertise, terminology control or a risk-based workflow, regulated teams face issues that surface during internal review, sponsor oversight or notified body interactions. These usually appear as evidence wording shifts, benefit-risk drift or version-control gaps.
Evidence wording loses precision
Clinical evidence wording, study descriptions, literature references and methodological detail may lose precision across languages, weakening how the underlying evidence reads in the translated CER.
Benefit-risk conclusions shift
Benefit-risk conclusions may change nuance, overstate or understate findings across languages, creating content your clinical evaluator and regulatory teams may need to revisit before notified body interactions.
Performance claims drift
Performance claims may drift away from the CER source or related SSCP, IFU and labelling content, creating inconsistencies across the manufacturer's regulated documentation portfolio.
Inconsistency with related documents
CER terminology may become inconsistent with PMCF, PMS, SSCP or technical documentation, undermining cross-document consistency that QARA, PRRC and reviewers expect.
Equivalence discussions mishandled
Equivalence discussions require careful handling of clinical, technical and biological distinctions across languages, which generic translation often fails to manage with the precision the topic requires.
AI fluency hides clinical risks
Generic AI translation may produce fluent but clinically risky wording in evidence summaries, benefit-risk statements or performance conclusions, which only qualified human medical review consistently identifies.
Our CER Translation Solutions
AbroadLink supports clinical and regulatory teams with CER translation, clinical evaluation report translation, MDR clinical documentation translation and clinical evaluation translation services. Each project is configured around device, CER section, clinical complexity and the regulatory context of the deliverable.
CER translation
Source-faithful CER translation by qualified medical device linguists, with clinical terminology, benefit-risk wording, references and structured review aligned with the regulatory context of the report.
Clinical evaluation report translation
Clinical evaluation report translation across CER updates, recurring revisions, SSCP alignment and supporting documentation under ISO-based workflows with structured terminology resources.
MDR clinical documentation translation
MDR clinical documentation translation covering CERs, PMCF, PMS, clinical evidence summaries and authority-facing materials, with MDR-aligned terminology and traceability through CertLink.
Clinical evaluation translation services
Clinical evaluation translation services for clinical evidence summaries, literature evaluations, equivalence discussions and benefit-risk conclusions, by linguists with medical writing and translation experience.
PMCF and PMS input support
Translation of PMCF and PMS inputs feeding into the CER, with consistency across post-market sources, evidence updates and CER cycles in the manufacturer's documentation portfolio.
ISO 17100 with independent revision
For higher-risk CER content, complex evidence, sensitive benefit-risk wording or class III device content, we apply ISO 17100 translation with independent revision and additional medical review.
Controlled AI workflows
Where suitable, aiHubLink supports AI pre-translation with client terminology and legacy CER content, always followed by qualified human medical validation under documented governance.
How Our Risk-Based CER Translation Workflow Works
Our workflow moves from CER intake to delivery of traceable translations, with risk-based workflow selection happening before translation begins. The objective remains accurate, complete and source-faithful translation. The selected workflow manages residual translation risk, review depth, cost and turnaround across CER cycles.
-
01
CER documentation intake
We review the CER and supporting documents, intended purpose, device class, CER structure, target Member States and previous translated versions, scoping the project against MDR context and clinical evaluation needs.
-
02
Device, audience and regulatory context
We assess device context, clinical evaluation purpose, target audience, intended notified-body-facing use and any specific Member State expectations relevant to the CER and its supporting clinical evaluation documentation.
-
03
Clinical evidence and version review
We review clinical evidence summaries, literature evaluations, equivalence discussions, PMS and PMCF inputs, references and any version changes from earlier CERs through translation memory analysis.
-
04
Risk-based workflow selection
We propose a workflow aligned with translation risk: translation plus QA for appropriate supporting sections and ISO 17100 with independent revision for higher-risk evidence, benefit-risk conclusions or class III device CERs.
-
05
Accuracy objective confirmation
We confirm that accurate, complete and source-faithful translation is the objective of every workflow. Clinical evidence, benefit-risk wording and references are flagged for particular care across review and QA steps.
-
06
Terminology and reference setup
We apply MDR-aligned terminology, translation memories, CER references, benefit-risk wording from the source, performance claims, PMCF/PMS references and any client style guides as binding references.
-
07
Translation and selected review steps
Qualified medical and clinical linguists translate the CER, with review, independent revision, AI translation validation or additional medical review applied according to the selected workflow before QA checks.
-
08
Delivery and CertLink access
Final CERs are delivered with a signed translation certificate identifying documents, project codes, translators and any AI model used, with feedback integrated into resources for future CER updates and PMCF cycles.
Controlled Translation Workflows for CERs
AbroadLink is an ISO 17100, ISO 9001 and ISO 13485-certified translation company with extensive experience in medical device, pharmaceutical, clinical and CER content. Our ISO 13485 implementation applies stricter linguist selection criteria than ISO 17100, supporting CER translation with qualified medical and clinical linguists, terminology control and structured review aligned with MDR expectations and notified-body-facing documentation.
For controlled AI translation, aiHubLink provides a structured environment combining custom AI pre-translation with client terminology, legacy CERs and qualified human medical validation. Signed translation certificates accessible through CertLink identify documents, project codes, translators and any AI model used, supporting Clinical Affairs, QARA, PRRC and CER Writer documentation alongside translation governance procedures.
| Context | How AbroadLink Supports It |
|---|---|
| CER translation | Clinical-language translation with medical device expertise |
| Clinical evidence | Careful handling of data, references and conclusions across languages |
| MDR documentation | Terminology aligned with regulated medical device content |
| Risk-based workflows | Review depth aligned with evidence sensitivity and content risk |
| Version control | Support for CER updates and related PMCF/PMS documents |
| Certificate access | CertLink records and delivery evidence where appropriate |
CER Translation FAQ
What is CER translation?
CER translation is the multilingual translation of Clinical Evaluation Reports and supporting documents that demonstrate the clinical safety, performance and benefit-risk profile of a medical device under MDR. It typically applies qualified medical and clinical linguists, MDR-aligned terminology, translation memories and structured review. AbroadLink delivers CER translation under risk-based workflows, with traceability through CertLink. The service supports regulated clinical documentation work, but clinical evidence validation, CER adequacy, notified body acceptance, QMS decisions and product approval remain with the manufacturer's clinical evaluator and qualified stakeholders.
What is clinical evaluation report translation?
Clinical evaluation report translation is the translation of CERs and clinical evaluation documentation across languages, applying medical and clinical translation expertise, terminology control and structured review. It covers intended purpose, clinical evidence, literature evaluations, equivalence discussions, PMS, PMCF, benefit-risk conclusions and performance claims. AbroadLink delivers clinical evaluation report translation with risk-based workflows tailored to device class, CER section, complexity and target markets. The service supports clinical and regulatory operations. Final CER approval, clinical evaluator decisions and notified body interactions remain owned by the manufacturer.
Who needs clinical evaluation translation services?
Clinical evaluation translation services are typically used by Clinical Affairs Managers, CER Writers, Medical Writers and Regulatory Affairs Managers in MedTech manufacturers managing CERs across product portfolios and target Member States. They support multilingual documentation for CER updates, PMCF cycles, SSCP alignment and authority-facing materials. AbroadLink delivers these services under ISO-based workflows, with traceability through CertLink. Final regulatory acceptance, notified body decisions, EUDAMED publication, clinical evidence sufficiency and product approval remain owned by the manufacturer and qualified stakeholders.
How is CER translation different from general medical translation?
CER translation is a specialised area of medical translation focused on Clinical Evaluation Reports under MDR. It requires not only medical and clinical language expertise but also familiarity with CER structure, clinical evidence, PMCF and PMS content, equivalence discussions, benefit-risk conclusions and performance claims. CERs feed into SSCPs, IFUs, labels and regulatory submissions, so consistency across documents matters. AbroadLink combines medical translation expertise with medical device experience and risk-based workflows. The work supports clinical evaluation, but does not, by itself, replace clinical evaluator or QARA responsibilities.
Why must CER translation be accurate?
CERs support the demonstration of clinical safety, performance and benefit-risk profile for medical devices under MDR. Translation must accurately and completely reflect the approved source content across clinical evidence, literature evaluations, equivalence discussions, PMCF and PMS inputs, benefit-risk conclusions and performance claims. Inaccurate translation can shift evidence wording or conclusions across languages, affecting how reviewers and notified bodies interpret the content. AbroadLink supports accurate CER translation under risk-based workflows, but accurate translation does not, by itself, guarantee clinical evidence sufficiency, CER adequacy or notified body acceptance, which depend on broader processes.
Does a lower-risk workflow mean lower translation accuracy?
No. The accuracy expectation for CER translation does not change with workflow. Accurate, complete and source-faithful translation is always the objective. Different workflows manage the risk of failing to achieve accurate clinical evaluation translation through different review depths, controls and evidence. A lower-risk workflow may be appropriate when the device, CER section, supporting document type, target audience, target markets and client-side controls support that choice. A higher-risk workflow applies when translation errors in clinical evidence, benefit-risk conclusions, performance claims, safety statements, equivalence discussions or PMCF/PMS findings could carry more serious consequences.
How does risk-based translation differ from CER approval?
The clinical evaluation requirement under MDR is that CER content reflects the approved source content accurately for each target market and use. That requirement applies regardless of workflow. AbroadLink's risk-based translation approach is a workflow decision: it determines how translation risk is managed through review depth, ISO 17100 revision, linguistic risk assessment and evidence. It does not change the accuracy requirement. CER approval, clinical evidence validation, regulatory strategy, notified body acceptance and EUDAMED interactions remain owned by the manufacturer's clinical evaluator, QARA team and the qualified bodies assessing the device.
Can AI be used for clinical evaluation report translation?
Yes, in a controlled way and with care. Through aiHubLink, AI pre-translation can use client terminology and legacy CERs as references for suitable sections, always followed by qualified human medical validation under ISO 9001, ISO 17100 and ISO 13485-based processes. The AI model used is identified on the signed translation certificate. For clinical evidence, benefit-risk wording, performance claims, equivalence discussions, PMCF/PMS content and class III device CERs, AI is positioned cautiously and used only when suitable. The workflow is agreed in advance with the client.
Does CER translation guarantee notified body acceptance?
No. CER translation, clinical evaluation report translation, MDR clinical documentation translation, AI-assisted translation, linguistic risk assessment and traceable evidence through CertLink support clinical and regulatory teams handling CER content under controlled processes. However, they do not guarantee MDR compliance, notified body acceptance, authority acceptance, clinical evidence sufficiency, clinical validity, CER adequacy, benefit-risk acceptability, QMS acceptance, product approval, CE marking, market access or business outcomes. These depend on device design, clinical evidence, regulatory strategy and the assessments of notified bodies, competent authorities and certification bodies, which remain the responsibility of the manufacturer.
Request CER Translation Services
If you need CER translation, clinical evaluation report translation, MDR clinical documentation translation or clinical evaluation translation services, talk to AbroadLink about scope, devices, CER sections and target Member States.
Working with an ISO 17100, ISO 9001 and ISO 13485-certified language partner with medical, clinical and medical device expertise, risk-based workflows, terminology control, controlled AI workflows and traceable certificates supports clinical and regulatory teams across CER cycles and related documentation.